siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model
Authors:
- 16 December 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (3) , 424-435
Abstract
Diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes mellitus, affecting nearly 50% of diabetic patients and leading to chronic pain, numbness, and progressive sensory and motor function loss. This study investigates the potential of siRNA-mediated silencing of poly (ADP-ribose) polymerase 1 (PARP1) to alleviate DPN in a rat model. PARP1 overactivation, driven by hyperglycemia-induced oxidative stress, exacerbates neuronal damage in DPN. Using chitosan nanoparticles (ChNPs) to deliver PARP1-targeting siRNA intrathecally in diabetic rats induced with streptozotocin (STZ) 55 mg/kg intraperitoneally, we conducted behavioral and physiological assessments, including Sciatic Functional Index (SFI), motor nerve conduction velocity (MNCV), grip strength, and pain sensitivity tests, alongside qRT-PCR analyses, to evaluate therapeutic outcomes. Our findings indicate statistically significant improvements, with siRNA ChNPs-mediated PARP1 silencing alleviating neuropathic symptoms in DPN rats (p < 0.001 for SFI and MNCV improvements). Biochemical analyses revealed reductions in oxidative stress markers, such as MDA, and increased antioxidant levels, including GSH, CAT, and SOD (p < 0.001). Pro-inflammatory cytokines and apoptotic markers, including NF-κB, IL6, IL1β, TNFa, TGF-β, CAS3, CAS9, BAK, and BAX, also showed significant reductions (p < 0.01), confirming the neuroprotective effects of PARP1 inhibition. These results highlight the potential of siRNA-based therapies targeting PARP1 as a promising therapeutic approach for DPN, paving the way for future research with clinical applications.Keywords
This publication has 74 references indexed in Scilit:
- Healthcare costs and medical utilization patterns associated with painful and severe painful diabetic peripheral neuropathyEndocrine, 2024
- A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin AmyloidosisNeurology and Therapy, 2020
- Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in DiabetesCurrent Diabetes Reports, 2019
- Inflammation as a Therapeutic Target for Diabetic NeuropathiesCurrent Diabetes Reports, 2016
- The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and DiseaseCell Metabolism, 2012
- The role of PARP1 in the DNA damage response and its application in tumor therapyFrontiers of Medicine, 2012
- Inflammation and diabetic nephropathyCurrent Diabetes Reports, 2006
- Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathyDiabetologia, 2004
- Attenuation of mechanical but not thermal hyperalgesia by electroacupuncture with the involvement of opioids in rat model of chronic inflammatory painBrain Research Bulletin, 2004
- Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectivesDiabetes/Metabolism Research and Reviews, 2002